Anika Therapeutics Inc
F:AKP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Anika Therapeutics Inc
F:AKP
|
US |
|
C
|
China State Construction International Holdings Ltd
XMUN:C4S1
|
HK |
|
Mitsui & Co Ltd
OTC:MITSF
|
JP |
|
N
|
National Australia Bank Ltd
XBER:NAL
|
AU |
|
Shanghai M&G Stationery Inc
SSE:603899
|
CN |
|
S
|
Starbucks Corp
BMV:SBUX
|
US |
|
HomeServe PLC
LSE:HSV
|
UK |
|
E
|
EQT Corp
SWB:EQ6
|
US |
|
Adani Enterprises Ltd
BSE:512599
|
IN |
|
C
|
Carvana Co
SWB:CV0
|
US |
|
Y
|
Yankey Engineering Co Ltd
TWSE:6691
|
TW |
|
C
|
Crocs Inc
SWB:C7N
|
US |
Anika Therapeutics Inc
Anika Therapeutics makes medical products that help doctors treat joint pain and support healing in bones and soft tissue. Its best-known products are based on hyaluronic acid, a substance used in joint injections and surgical care, and it also sells orthopedic and tissue-healing products used in procedures such as knee, hip, and sports-medicine treatment. The company sells mainly to hospitals, surgeons, and other healthcare providers, usually through medical-device distributors and direct sales teams. Its customers use Anika’s products in procedures where they need a material that can cushion joints, reduce friction, or help repair damaged tissue. Anika makes money by selling these products to the healthcare supply chain and by supporting repeat use in established procedures. What makes Anika different is that it sits at the intersection of drug-like biomaterials and medical devices. It is not a broad hospital supplier; it focuses on a narrower set of orthopedic and regenerative-care products where a specific material science matters. That gives the company a specialized role in treatment areas where doctors need trusted implantable or injectable products rather than general equipment.
Anika Therapeutics makes medical products that help doctors treat joint pain and support healing in bones and soft tissue. Its best-known products are based on hyaluronic acid, a substance used in joint injections and surgical care, and it also sells orthopedic and tissue-healing products used in procedures such as knee, hip, and sports-medicine treatment.
The company sells mainly to hospitals, surgeons, and other healthcare providers, usually through medical-device distributors and direct sales teams. Its customers use Anika’s products in procedures where they need a material that can cushion joints, reduce friction, or help repair damaged tissue. Anika makes money by selling these products to the healthcare supply chain and by supporting repeat use in established procedures.
What makes Anika different is that it sits at the intersection of drug-like biomaterials and medical devices. It is not a broad hospital supplier; it focuses on a narrower set of orthopedic and regenerative-care products where a specific material science matters. That gives the company a specialized role in treatment areas where doctors need trusted implantable or injectable products rather than general equipment.
Revenue: Anika reported first-quarter revenue of $29.6 million, up 13% year over year, with strength in both commercial channels and OEM.
Margins: Gross margin improved sharply to 64% from 56% a year ago, helped by higher volume, better manufacturing execution and lean initiatives, though management said this level is unlikely to hold every quarter.
Integrity: The Integrity franchise continued to accelerate, with U.S. procedures up 35% year over year, revenue of nearly $2 million, and more than 3,000 cases now completed.
Guidance: Full-year 2026 guidance was unchanged, including revenue of $114 million to $122.5 million and adjusted EBITDA at 5% to 10% of revenue.
Pipeline: Hyalofast’s FDA review is ongoing, CINGAL’s enrollment remains on track, and the company highlighted an early regenerative suture and tape program as a longer-term opportunity.
Capital return: The company completed its first $15 million stock repurchase program and has already bought $15 million more under a second 10b5-1 plan.
